secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0000950170-25-030826
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health reports Q4 2024 net loss $25.0M; REMAIN-1 enrollment surges to 189+ patients
--------------------------------------------------------------------------------

- Q4 2024 net loss $25.0M vs $19.2M in Q4 2023; R&D expense rose to $20.3M from $10.1M.
- Cash and equivalents $67.5M; cash runway extended into 2026 after pausing T2D Revita programs.
- REMAIN-1 pivotal study enrolled >189 patients across 13 sites; midpoint data expected Q2 2025, full enrollment summer 2025.
- Rejuva RJVA-001 CTA for T2D submission expected H1 2025; preliminary data (if authorized) in 2026.
- Strategic shift: focus Revita on weight maintenance, pause T2D Revita programs (REVITALIZE-1, Germany Registry).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025030826/0000950170-25-030826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025030826/guts-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-030826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer